1. 528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours. (September 2015) Authors: Spicer, J.; Awada, A.; Brunsvig, P.; Saunders, A.; Olsen, W.M.; Nicolaisen, B.; Rekdal, O.; Laruelle, M.; Marjuadi, F.; Vakili, J.; Aftimos, P.; Barthelemy, P.; Deva, S.; Baurain, J.F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. (November 2018) Authors: Arkenau, H.-T.; Italiano, A.; Mak, G.; Toulmonde, M.; Baird, R.D.; Garcia-Corbacho, J.; Plummer, R.; Flynn, M.; Forster, M.; Wilson, R.H.; Tosi, D.; Adenis, A.; Donaldson, K.; Posner, J.; Kawabata, I.; Arimura, A.; Deva, S.; Spicer, J. Journal: European journal of cancer Issue: Volume 103(2018) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗